Outcomes associated with once‐daily versus multiple‐daily dosing of buprenorphine/naloxone for opioid use disorder.

Autor: Allen, Sarah M., Nichols, Taylor A., Fawcett, Janet, Lin, Show
Předmět:
Zdroj: American Journal on Addictions; May2022, Vol. 31 Issue 3, p173-179, 7p, 3 Charts
Abstrakt: Background and Objectives: Clinical studies examining once‐daily versus multiple‐daily dosing of buprenorphine/naloxone in patients with opioid use disorder (OUD) in the absence of comorbid pain are lacking. Methods: This retrospective chart review aimed to compare 100 patients prescribed single‐daily buprenorphine/naloxone (n = 50) to those prescribed multiple‐daily buprenorphine/naloxone (n = 50) to elucidate the impact that dosing frequency has on negative urine drug screens (UDS) and the number of relapses in OUD. Results: The once‐daily cohort produced 84% negative UDSs compared with 74% in the multiple‐daily cohort which was statistically significant (p =.034). There were a total of 43 relapses reported in the once‐daily cohort, compared with 141 relapses in the multiple‐daily cohort (p <.001). The average number of relapses per patient in the single‐daily cohort was 0.68 compared with the multiple‐daily cohort average of 2.16 (p <.001). In the once‐daily cohort, 14% of patients experienced at least one relapse throughout the study, compared with 31% in the multiple‐daily cohort (p <.002). There were no significant differences between time to relapse, adherence to treatment, or treatment retention. Statistically significantly more patients in the multiple‐daily cohort were using methamphetamines (p =.005); there were no significant differences between groups with the use of any other illicit or non‐prescribed substances. Discussion and Conclusions: Once‐daily dosing was associated with more negative UDSs and fewer opioid relapses compared with multiple‐daily dosing. Scientific Significance: This was the first study to evaluate buprenorphine/naloxone dosing frequency for opioid use disorder, in the absence of chronic pain. Additional studies evaluating optimal dosing schedules for relapse prevention are warranted. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje